WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/050500    International Application No.:    PCT/SE2011/000179
Publication Date: 19.04.2012 International Filing Date: 11.10.2011
C07D 215/56 (2006.01), A61K 31/4365 (2006.01), A61K 31/4704 (2006.01), A61P 3/10 (2006.01), A61P 17/06 (2006.01), A61P 35/00 (2006.01), C07D 495/04 (2006.01)
Applicants: IMMUNAHR AB [SE/SE]; Prästasvängen 21 S-224 78 Lund (SE) (For All Designated States Except US).
PETTERSSON, Lars [SE/SE]; (SE) (For US Only)
Inventors: PETTERSSON, Lars; (SE)
Agent: AWAPATENT AB; Att. Tomas Lundquist Box 45086 S-104 30 Stockholm (SE)
Priority Data:
1001012-2 14.10.2010 SE
Abstract: front page image
(EN)The present invention relates to compounds which are 1, 2-dihydro-4- hydroxy-2-oxo-quinoline-3-carboxanilides, their thieno-pyridone analogs, and prodrugs thereof. This invention specifically relates to such derivatives containing an N-hydrogen in the carboxanilide moiety and which exhibit modulating activity towards the aromatic hydrocarbon receptor (AhR), and, specifically, also to prodrugs thereof. The present invention also relates to use of said compounds as a medicament, and for the treatment of cancer, autoimmune disorders and other disorders with an immunological component, and a pharmaceutical composition comprising one or more of said compounds and a method of treatment.
(FR)La présente invention concerne des composés qui sont des 1,2-dihydro-4-hydroxy-2-oxo-quinoléine-3-carboxanilides, leurs analogues thiéno-pyridones et des promédicaments de ceux-ci. De façon spécifique, cette invention concerne de tels dérivés contenant un N-hydrogène dans la fraction carboxanilide et présentant une activité de modulation envers le récepteur des hydrocarbures aromatiques (AhR), et, de façon spécifique, également les promédicaments de ces dérivés. La présente invention concerne également l'utilisation desdits composés en tant que médicament et pour le traitement du cancer, des troubles auto-immuns et d'autres troubles ayant une composante immunologique, et une composition pharmaceutique comprenant un ou plusieurs desdits composés et une méthode de traitement.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)